Not the first time I have heard of or seen electroporation used in promising technologies before. The first use I saw was with Cytogenix use of electroporation as a possible delivery of their SS DNA. That was over a decade ago though. Results look very promising indeed. More than a few companies are looking at reducing side effects from radiation and chemo for cancers. Skin cancer is unique in that the target can be just below topical.
The trial was not expected to show anything more than the promise of the technology. It will never be used as a monotherapy. Do you not understand this?
ONCS is building part of the solution. Most cancer therapies will be combinatorial in the future. Think of the BASF analogy I've mentioned numerous times on this board in the past.
That's the shorts argument I'm sure. Most longs that I know who have owned the stock and know the company inside and out feel like the results met expectations.
Market Data 
Markets 
AI
